聚合物-药物结合物 代肝 一种特莫佐洛米德中间体和氧化用于针对多形质母细胞瘤的增强化疗法
1MOE Key Laboratory of High Performance Polymer Materials and Technology, and Department of Polymer Science & Engineering, School of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210023, China.
ACS applied bio materials
|February 26, 2024
概括
这项研究开发了一种聚合物 - 药物合物 (PDC) 用于多种质母细胞瘤 (GBM) 治疗. 新型PDC同时提供Temozolomide (TMZ) 前药和氧化 (NO),显示对抗性GBM细胞的协同作用.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 聚合物药物合物 (PDCs) 在癌症治疗中提供了多反应性药物递送的潜力.
- 泰莫佐洛米德 (TMZ) 用于治疗多种质母细胞瘤 (GBM),但其疗效有限.
- 现有的TMZ PDC面临着稳定性和治疗有效性的挑战.
研究的目的:
- 为增强质母细胞瘤治疗开发一个响应环境的PDC.
- 使用单一平台共同提供TMZ中间体 (MTIC) 和氧化 (NO).
- 在质母细胞瘤细胞中克服TMZ抵抗.
主要方法:
- 合成一种具有特定功能的两性triblock共聚合物 (P1-SNO).
- 纳入TMZ中间体 (MTIC) 和氧化 (NO) 供体.
- 使用二硫化物键对氧化还原反应和S-尼特罗斯醇对光/热反应.
- 评估MTIC和NO释放机制以及在GBM细胞上的体外疗效.
主要成果:
- 在减少谷氨的反应中,P1-SNO成功释放了MTIC.
- 在暴露于光或热量时,气体NO从P1-SNO释放出来.
- 实验室研究表明,MTIC和NO对TMZ敏感和TMZ耐药的GBM细胞具有协同作用.
- 在克服TMZ阻力方面,P1-SNO系统显示出有前途.
结论:
- 开发的响应环境的PDC系统使MTIC和NO的联合交付成为可能.
- 这种双交付方法表现出对抗GBM的协同抗癌效应.
- P1-SNO结合物有望提高基于TMZ的质母细胞瘤治疗的疗效.
更多相关视频
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


